Overview

A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis

Status:
Completed
Trial end date:
2016-02-04
Target enrollment:
Participant gender:
Summary
To determine the dose or doses of PF-00547659 that will be the most effective to improve or halt the disease symptoms in patients with moderate to severe ulcerative colitis.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Shire